Analytical Data
-
Gene name
CLDN19
- Application
-
Alternative Names
CLDN19; Claudin-19
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8N6F1
-
Expression Region
1-211aa
-
AA Sequence
MANSGLQLLGYFLALGGWVGIIASTALPQWKQSSYAGDAIITAVGLYEGLWMSCASQSTGQVQCKLYDSLLALDGHIQSARALMVVAVLLGFVAMVLSVVGMKCTRVGDSNPIAKGRVAIAGGALFILAGLCTLTAVSWYATLVTQEFFNPSTPVNARYEFGPALFVGWASAGLAVLGGSFLCCTCPEPERPNSSPQPYRPGPSAAAREYV
-
Molecular Weight
48.95 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLDN19 (Claudin-19) is a member of the claudin family of transmembrane proteins, which are crucial components of tight junctions that regulate paracellular permeability in epithelial tissues. Research has shown that CLDN19 plays a significant role in maintaining the integrity of the blood-brain barrier as well as being involved in renal function, particularly in the proximal tubule of the kidney. Mutations in the CLDN19 gene are linked to various pathologies, including a rare genetic disorder known as hypomagnesemia with secondary epilepsy and other neurological problems. Given its importance in cell adhesion and barrier function, CLDN19 is a target of interest for studying both normal physiological processes and disease mechanisms. In recent years, efforts have focused on elucidating the structure and function of CLDN19 through the production of recombinant proteins, which can provide insights into its molecular interactions and potential therapeutic implications. Advanced techniques such as crystallography and biophysical characterization of CLDN19 recombinant proteins allow for a deeper understanding of its role in epithelial barrier function, as well as its potential as a biomarker or therapeutic target in conditions associated with altered tight junction dynamics. Overall, the study of CLDN19 recombinant protein is essential for uncovering the cellular and molecular bases of disorders linked to its dysfunction, paving the way for innovative clinical strategies.
